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Background: Currently, in the field of general anesthesia, balanced anesthesia in combination with analgesic,
hypnotic, and muscle relaxant is commonly used. Remifentanil is the standard analgesic used in balanced
anesthesia, and has contributed greatly to reduce the physical stress of the patient during surgery. We compared
the stress response suppression effect of remifentanil by measuring stress hormones in 2 groups treated with
different analgesic doses in orthopedic surgery using a tourniquet.
Methods: Twenty patients were randomly divided into 2 groups (10 patients each) undergoing maintenance of
general anesthesia with 0.25 μg/kg/min remifentanil and sevoflurane (Group A) and 1.0 μg/kg/min remifentanil and
sevoflurane (Group B). Hemodynamic changes, adrenocorticotropic hormone (ACTH), cortisol, antidiuretic hormone
(ADH), adrenaline (Ad), noradrenaline (NAd), dopamine (DOA), insulin, and blood glucose were measured at the
initiation of general anesthesia,10 minutes after the initiation of tourniquet application, and immediately before and
10 minutes after the completion of tourniquet application.
Results: ACTH, cortisol, ADH, Ad, and NAd levels in Group B were significantly lower (ACTH and cortisol: P < 0.01,
ADH, Ad, and NAd: P < 0.05) than those in Group A. No significant differences were noted in DOA, insulin, or blood
glucose levels between the groups.
Conclusion: Anesthesia management with high-dose remifentanil (1.0 μg/kg/min) suppressed intraoperative
tourniquet pain-induced stress hormone release, suggesting its usefulness in stabilizing hemodynamics.
Trial registration: JMA-IIA00094
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In orthopedic surgery using a tourniquet application (TA),
tourniquet pain increases as the duration of avascularization
becomes prolonged, and intraoperative hemodynamic
variations increase, such as elevations in blood pressure and
tachycardia, which may make anesthesia management
difficult. Generally, tourniquet pain-induced stress re-
actions, such as elevations in blood pressure, undergo
symptomatic treatment, such as the administration of
additional analgesics and antihypertensive drugs, but
anesthesia management with a low risk of adverse events is
necessary to reduce the risk of complications. When strong* Correspondence: shinoda@an.em-net.ne.jp
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reproduction in any medium, provided the orstressful stimulation, such as tourniquet pain, is expected,
anesthesia management at a higher analgesic level than a
conventional level may facilitate anesthesia with stable
hemodynamics, which is gentler on the patient’s body.
Remifentanil can be readily administered at a sufficient
analgesic dose during surgery because the analgesic dose
is highly adjustable and the drug does not accumulate due
to a short context-sensitive half-time [1,2].
In this study, we investigated the stress response
suppression effect of remifentanil by measuring and
comparing the hemodynamics and stress hormone
levels of patients treated at 2 different analgesic doses
in orthopedic surgery using a TA.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Anesthetic protocol. *Case of hemodynamic suppression (bradycardia, hypotension). - systolic blood pressure (SBP) 80 mmHG continued
for 1 min: administration of phenylephrine 0.1 mg or ephedrine 8 mg. - Heart rate (HR) 40 beats/min continued for 1 min: administration of atropine
0.5 mg. * Case in stress response (tachycardia, hypertension). - administration of remifentanil 1 μg/kg bolus (0.1 mL per 10 kg body weight). LOC, loss
of consciousness. INTB, tracheal intubation. IV-PCA, intravenous patient controlled analgesia.
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This study was performed after approval by the Ethics
Committee of Showa University Fujigaoka Hospital and
the patient gave informed consent.
Subjects were 20 patients aged over 16 years old with
the American Society of Anesthesiologists (ASA) physical
status I-II undergoing orthopedic surgery of the lower
limbs (knee joint) using a TA. Patients with the following
conditions were excluded: poorly controlled hypertension,
abnormal glucose tolerance with 5.5% or higher HbA1c,
past medical history of steroid hormone administration,
requirement of intraoperative blood transfusion, past
medical history of narcotic analgesic administration, and
complications of Parkinson’s disease.
As this is an exploratory study, we established the target
number of patients, assuming that blood glucose levels may
indirectly represent analgesic levels. According to previous
data from patients who underwent cardiac surgery, blood
glucose levels, which may become a parameter of the
analgesic level, were 118 mg/dL in the 0.25 μg/kg/min
remifentanil group and 92 mg/dL in the 1.0 μg/kg/min
remifentanil group [3]. As the mean blood glucose level isTable 1 Demografic characteristics of the study groups
Group A Group B P
value(0.25 μg/kg/min) (1.0 μg/kg/min)
Number of patients 10 10 -
Gender (male/female 5/5 5/5 1.0
Age (year) 49.4 ± 27.2 45.6 ± 30.1 0.8
Height (cm) 162.9 ± 10.9 160.9 ± 10.5 0.7
Body weight (kg) 62.1 ± 10.3 60.9 ± 13.7 0.8
ASA Physical status (1/2) 5/5 6/4 0.7approximately 120 mg/dL, based on the results of a clinical
observation of anesthesia control, we assumed that the
mean blood glucose levels in Groups A and B were
120 and 90 mg/dL, respectively, in this study. When
establishing the standard deviation as 20 mg/dL, a 0.05 level
of significance (paired) and 80% power of detection in the
two groups, 16 patients (n = 8 per group), were estimated
to be necessary for the t-test to detect a difference in the
mean between the groups. Considering dropout cases, we
established the number of patients to be registered as 20
(10 per group)
This study was designed as a randomized controlled
trial. Subjects were registered in a patient allocation table
by block randomization, and were allocated to either
Group A or Group B for investigation in accordance with
this allocation table.
Patients stopped eating and drinking from 21:00 on the
day before surgery and general anesthesia was initiated
between 8:30 and 9:00 a.m. in all patients.
After entering the operation room, a venous line using
a 20-G needle and an arterial line for blood sampling
using a 22-G needle were established in the left forearm
and radial artery, respectively.
General anesthesia was induced with 1.0 mg/kg propofol,
0.8 mg/kg rocuronium, and remifentanil (Group A:
0.25 μg/kg/min, Group B: 1.0 μg/kg/min), followed by mask
ventilation with 100% oxygen for 3–4 minutes and
then tracheal intubation. Anesthesia was maintained
by continuous intravenous administration of remifentanil
(Group A: 0.25 μg/kg/min, Group B: 1.0 μg/kg/min) and
sevoflurane was administered to adjust the BIS (Bispectral
index) value to 40–50. For intraoperative infusion, only
extracellular fluid containing 1% glucose was administered
(7.0-8.0 ml/hr). For postoperative analgesia, both Groups
Table 2 Comparison of surgery and anesthesia features between the study groups
Group A Group B P-value
(0.25 μg/kg/min) (1.0 μg/kg/min)
Surgery 0.8
Total knee replacement 5 4
Arthroscopic anterior cruciate ligament reconstruction 4 4
Arthroscopic meniscal resection 1 2
Anesthesia time (min) 172.0 ± 23.6 170.0 ± 21.2 0.8
Operation time (min) 125.0 ± 23.3 123.0 ± 21.0 0.8
Tourniquet application time (min) 96.2 ± 5.7 100.2 ± 13.3 0.4
Fluid volume (mL) 1325.0 ± 178.3 1340.0 ± 269.6 0.9
Urine volume (mL) 250.0 ± 150.9 740.0 ± 247.6 < 0.001**
Blood loss (mL) 50.5 ± 56.0 47.5 ± 52.1 0.9
Average consumption of sevoflurane (%) 1.3 ± 0.1 1.0 ± 0.1 < 0.001**
** Urine volume and average consumption of sevoflurane were significantly higher in Group B than Group A.
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tion of 100 μg of fentanyl 30 minutes before completion
of surgery and intravenous patient controlled analgesia
with fentanyl was initiated after completion of general
anesthesia (Figure 1). Blood was collected from the arterial
line at the start of anesthesia (before drug consumption),
10 minutes after TA start, just before TA end, and 10 mi-
nutes after TA end, 4 times in total, and adrenocorticotro-
pic hormone (ACTH), cortisol, antidiuretic hormone
(ADH), adrenaline (Ad), noradrenaline (NAd), dopamine
(DOA), insulin, and blood glucose were measured. Sample
analysis was performed by Health Sciences Research
Institute East Japan Co., Ltd. (Saitama, Japan). The blood
pressure (mean arterial pressure, MAP), heart rate, body
temperature, urine volume, blood loss, and average
consumption of sevoflurane were recorded as conven-
tional monitoring items. The average consumption of
sevoflurane was calculated using the following equation:
Amount of sevoflurane used (mL) ÷ 3.3 ÷ vaporizer flowFigure 2 Changes in mean arterial blood pressure (MAP), and heart r
Changes from the baseline (ANES start) values were different (* P < 0.05, **
different (# P < 0.05, ## P < 0.01) than at baseline within the same group usi
induction of anesthesia. TA: Tourniquet application.rate (L/min) ÷ duration of administration. All data are
presented as the mean ± standard deviation. Statistical
analysis was performed using the statistical software
JMP©8.0.1(SAS Institute Japan). Between group compari-
sons were performed employing the chi-square test for
nominal scales, unpaired t-test and dunnett test for con-
tinuous scales, and p < 0.05 was regarded as significant.
Results
There were no significant differences in the following
surgical background items: age, gender, height, body
weight, ASA physical status, duration of anesthesia,
operation time, duration of TA, infusion volume, and
blood loss. No significant difference was noted in
intraoperative total infusion volume, but intraoperative
urine volume in Group B (740.0 ± 247.6 mL) was
significantly larger than that in A (250.0 ± 150.9 mL)
(P < 0.01) The average consumption of sevoflurane in
Group A (1.3 ± 0.1%) was significantly higher thanate (HR). Data are expressed as the mean ± standard deviation.
P < 0.01) between the groups using unpaired t-test. Mean value was
ng dunnett test. ANES start: Just before drug consumption for
Figure 3 Changes in adrenocorticotropic hormone (ACTH), cortisol, and antidiuretic hormone (ADH). Data are expressed as the
mean ± standard deviation. Changes from the baseline (ANES start) values were different (* P < 0.05, ** P < 0.01) between the groups using unpaired
t-test. Mean value was different (# P < 0.05, ## P < 0.01) than at baseline within the same group using dunnett test. ANES start: Just before drug
consumption for induction of anesthesia. TA: Tourniquet application. Standard value: ACTH (7.2-63.3 pg/mL), cortisol (4.5-21.1 pg/mL),
ADH (0.3-3.5 pg/mL).
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Mean arterial blood pressure (MAP) in Group A was
significantly higher than just before TA end (Group
A: 100.4 ± 11.9, Group B: 81.6 ± 13.4 mmHg, P < 0.05).
The course of the heart rate was similar in the 2
groups, showing no significant differences throughout
surgery (Figure 2). There were no significant differ-
ences in the BIS value and body temperature between
the groups. The highest ACTH level was noted just before
TA end in Group A. In contrast, it decreased with time in
Group B. A significant difference was noted between the
groups just before TA end (Group A: 95.1 ± 84.2, Group
B: 4.9 ± 1.6 pg/ml, P < 0.01) and 10 min after TA end
(Group A: 59.7 ± 55.7, Group B: 7.7 ±10.2 pg/ml, P < 0.01).
Cortisol levels were similar between the 2 groups until
10 min after TA start, but cortisol levels in Group A
became higher than those in B and continued to riseFigure 4 Changes in adrenaline (Ad), noradrenaline (NAd), and dopam
Changes from the baseline (ANES start) values were different (* P < 0.05, **
different (# P < 0.05, ## P < 0.01) than at baseline within the same group usi
induction of anesthesia. TA: Tourniquet application. Standard value: Ad (<1thereafter. A significant difference was noted between
the groups just before TA end (Group A: 12.1 ± 7.8,
Group B: 4.9 ± 1.5 μg/dl, P < 0.05) and 10 min after TA end
(Group A: 14.8 ± 7.8, Group B: 5.2 ± 2.4 μg/dl, P < 0.01).
ADH levels rose with the avascularization time in Group
A, but no rise was noted in Group B. No significant differ-
ence was noted between the groups (Figure 3). Ad levels
tended to rise in both groups, but the rise in Group B was
smaller than that in Group A. A significant difference was
noted between the groups 10 min after TA end (Group
A: 21.4 ± 23.4, Group B: 7.2 ±8.3 pg/ml, P < 0.05) and
just before TA end (Group A: 137.6 ± 135.0, Group B:
35.4 ± 69.9 pg/ml, P < 0.05). The variation pattern of
NAd and DOA levels was similar throughout surgery, but
both levels in Group B were lower than those in Group A,
but this difference was not significant (Figure 4). The vari-
ation pattern of insulin levels was similar throughoutine (DOA). Data are expressed as the mean ± standard deviation.
P < 0.01) between the groups using unpaired t-test. Mean value was
ng dunnett test. ANES start: Just before drug consumption for
00 pg/mL), NAd (140–450 pg/mL), DOA (< 20 pg/mL).
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those in Group A. No significant difference was noted
between the groups. No significant difference was noted
in blood glucose levels between the groups throughout
surgery (Figure 5). No nausea, vomiting, or shivering
occurred after surgery in any patient. All patients safely
awakened and were extubated in the operation room.
Memories during surgery were confirmed the following
day, based on which no intraoperative awareness was
suspected in any patient of either group.
Discussion
The recent objective of anesthesia management is
stress-free early recovery after surgery [4]. Surgical
stress is closely related to catecholamine synthesis and
secretion by the adrenal medulla, and an increase in
catecholamine secretion has been reported to inhibit
cellular immunity [5]. It has also been reported that inhib-
ition of stress reactions prevented surgical stress-induced
perioperative reductions in immune function [6].
Surgical stress elevates the levels of stress hormones
(ACTH, cortisol, ADH, Ad, NAd, and DOA) and inflam-
matory cytokines (TNF-α, IL-1, IL-2, and IL-6) in the
body [7]. These promote insulin resistance, gluconeo-
genesis, and glycolysis and impair insulin secretion,
resulting in intraoperative stress-induced hyperglycemia
[8]. Intraoperative hyperglycemia has been reported to be
an independent risk factor of severe adverse inhospital
outcomes (Odds ratio 7.2) [9] and has been suggested
to influence mortality [10]. It has also been suggested
that ACTH and cortisol release are involved in the
development of deep vein thrombosis and pulmonary
embolism [11]. Based on these findings, inhibition of
stress-induced hyperglycemia and stress hormone release
by intraoperative anesthesia management may be useful in
improving patient outcomes. It has already been reportedFigure 5 Changes in insulin and blood glucose. Data are expressed as t
values were different (* P < 0.05, ** P < 0.01) between the groups using unp
baseline within the same group using dunnett test. ANES start: Just before
application. Standard value: insulin (2.2-12.4 pg/mL), blood glucose (70–109that stress hormone and cytokine release and intraoperative
hyperglycemia were inhibited by anesthesia management
using remifentanil [3,12-14]. The strong analgesic ac-
tion of high-dose (1.0 μg/kg/min) remifentanil may
have suppressed tourniquet pain-induced stress stimulation,
stabilized circulatory dynamics, and significantly inhibited
stress hormone release in our study.
On the other hand, no significant difference was noted
in blood glucose levels between the groups and no
stress-induced hyperglycemia occurred, suggesting that
insulin secretion was maintained at a higher level in
Group A than that in Group B, although the difference
was not significant, avoiding hyperglycemia in Group A.
However, in a study in which anesthesia with sevoflurane
alone and that with remifentanil and propofol anesthesia
were compared in patients during open hysterectomy,
stress hormone and blood glucose levels were lower in the
TIVA group [9]. In a study in which 5 doses (0.25, 1.0, 2.5,
and 5.0 μg/kg/min) of remifentanil were compared in
pediatric patients during cardiac surgery, cortisol and
glucose level elevations were suppressed in the group
treated with remifentanil at 1.0 μg/kg/min or higher [3]. In
our previous study in which changes in blood glucose
levels during laparoscopic surgery were investigated in
groups treated with remifentanil at 0.25 and 1.0 μg/kg/min
[15], blood glucose levels were significantly rose in the
0.25 μg/kg/min remifentanil treatment group.
These preceding studies suggest that the blood glucose
level may serve as an index of surgical stress inhibition.
However, the blood glucose level is influenced by
various factors, and no correlation was noted between
the stress hormone and blood glucose levels, suggesting
that tourniquet pain and organ-injuring stress simulation
are different.
The increase in urine volume observed in Group B
(1.0 μg/kg/min) may have been due to the suppressionhe mean ± standard deviation. Changes from the baseline (ANES start)
aired t-test. Mean value was different (# P < 0.05, ## P < 0.01) than at
drug consumption for induction of anesthesia. TA: Tourniquet
mg/dL).
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high in Group A (0.25 μg/kg/min) and there was no
difference in infusion volumes between the 2 groups.
Conclusion
Anesthesia management with high-dose remifentanil
(1.0 μg/kg/min) suppressed tourniquet pain-induced stress
hormone release during orthopedic surgery of the
limbs using a TA, suggesting its usefulness in stabilizing
hemodynamics. This protocol should also be evaluated in
patients treated with various surgeries. It may be difficult
to accurately evaluate intraoperative stress unless stress
hormones can be measured simply in an operation room
at a low cost. As an alternative, the blood glucose level and
urine volume may serve as indices of the analgesic effect
because these can be measured simply during surgery.
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